Item Type No Grouping

Article

Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. (2024) Davide Arillotta, Giuseppe Floresta, G. Duccio Papanti Pelletier, Amira Guirguis, John Martin Corkery, Giovanni Martinotti and Fabrizio Schifano

Exploring the Association Between Suicidal Thoughts, Self-Injury, and GLP-1 Receptor Agonists in Weight Loss Treatments: Insights from Pharmacovigilance Measures and Unmasking Analysis. (2024) Amira Guirguis, Stephania Chiappini, P G Duccio Papanti, Rachel Vickers-Smith, Daniel Harris, John Corkery, Davide Arillotta, Giuseppe Floresta, Giovanni Martinotti and Fabrizio Schifano

Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions. (2024) Giuseppe Floresta, Davide Arillotta, Valeria Catalani, G. Duccio Papanti Pelletier, John Corkery, Amira Guirguis and Fabrizio Schifano

Benzodiazepine Boom: Tracking Etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques. (2024) Anthony Mullin, Mark Scott, Giorgia Vaccaro, Giuseppe Floresta, Davide Arillotta, Valeria Catalani, John M Corkery, Jacqueline L Stair, Fabrizio Schifano and Amira Guirguis

GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. (2023) Davide Arillotta, Giuseppe Floresta, Amira Guirguis, John Martin Corkery, Valeria Catalani, Giovanni Martinotti, Stefano L. Sensi and Fabrizio Schifano

Psilocybin for Depression: From Credibility to Feasibility, What’s Missing? (2022) Antonio Munafò, Davide Arillotta, Guido Mannaioni, Fabrizio Schifano, Renato Bernardini and Giuseppina Cantarella

Psychonauts’ psychedelics: a systematic, multilingual, web-crawling exercise. (2021) Valeria Catalani, John Martin Corkery, Amira Guirguis, Flavia Napoletano, Davide Arillotta, Caroline Zangani, Alessandro Vento and Fabrizio Schifano

Covid-19 pandemic impact on substance misuse: a social media listening, mixed method analysis. (2021) Davide Arillotta, Amira Guirguis, John Martin Corkery, Norbert Scherbaum and Fabrizio Schifano

Identifying new/emerging psychoactive substances at the time of COVID-19; a web-based approach. (2021) Valeria Catalini, Davide Arillotta, John Martin Corkery, Amira Guirguis, Alessandro Vento and Fabrizio Schifano

The psychonauts' world of cognitive enhancers. (2020) Flavia Napoletano, Fabrizio Schifano, John Martin Corkery, Amira Guirguis, Davide Arillotta, Caroline Zangani and Alessandro Vento

Novel opioids: systematic web crawling within the e-psychonauts’ scenario. (2020) Davide Arillotta, Fabrizio Schifano, Flavia Napoletano, Caroline Zangani, Liam Gilgar, Amira Guirguis, John Martin Corkery, E Aguglia and alessandro vento

The clinical challenges of synthetic cathinones. (2019) Fabrizio Schifano, Flavia Napoletano, Davide Arillotta, Caroline Zangani, Liam Gilgar, Amira Guirguis, John Corkery and Alessandro Vento

Other

Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals. (2022) Fabrizio Schifano, Valeria Catalani, Safia (Sophia) Sharif, Flavia Napoletano, John Corkery, Davide Arillotta, Suzanne Fergus, Alessandro Vento and Amira Guirguis

New Psychoactive Substances (NPS) and Serotonin Syndrome onset: a Systematic Review. (2021) Fabrizio Schifano, Stephania Chiappini, John Corkery, Norbert Scherbaum, Flavia Napoletano, Davide Arillotta, Valeria Catalani, Alessandro Vento, Mauro Pettorruso, Giovanni Martinotti, Massimo di Giannantonio and Amira Guirguis

The e-psychonauts’ ‘Spiced’ World; assessment of the synthetic cannabinoids’ information available online. (2020) Caroline Zangani, Fabrizio Schifano, Flavia Napoletano, Davide Arillotta, Liam Gilgar, Amira Guirguis, John Martin Corkery, Orsola Gambini and Alessandro Vento